Targanta Therapeutics Corp (MM) (NASDAQ:TARG)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Targanta Therapeutics Corp (MM) Charts. Click Here for more Targanta Therapeutics Corp (MM) Charts.](/p.php?pid=staticchart&s=N%5ETARG&p=8&t=15)
Targanta Therapeutics Corporation (NASDAQ: TARG) today announced the
presentation of studies detailing oritavancin’s
superior in vitro potency at the combined annual meetings of
the Interscience Conference on Antimicrobial Agents and Chemotherapy
(ICAAC) and the Infectious Disease Society of America (IDSA), taking
place in Washington, DC. These presentations highlight oritavancin’s
potent activity against a variety of gram-positive bacteria, including
those strains either non-susceptible or resistant to currently available
agents. The preclinical research underscores oritavancin’s
potential to address the limitations of currently marketed therapies for
serious gram-positive infections.
Throughout the meeting, multiple posters and slide presentations will
describe oritavancin’s key attributes
including:
Superior In Vitro Potency
Several presentations of data will showcase oritavancin’s
superior in vitro potency across a broad range of susceptible,
non-susceptible, and resistant pathogens relative to currently available
antibiotic treatments including vancomycin, linezolid, daptomycin and
teicoplanin.
Consistent Activity Against Contemporary Strains, Globally
Contemporary surveillance studies show that oritavancin retains potency
against a myriad of recent isolates of gram-positive pathogens surveyed
worldwide. Oritavancin is highly active against recently
isolated staphylococcal, enterococcal and streptococcal strains.
The schedule of presentations is as follows:
DATE
TIME
Type
AUTHOR
TITLE
Saturday,
October 25
12:15 p.m. – 1:15 p.m.
Poster
Badal
Oritavancin: Comparative in-vitro Activity Against Hospital-Acquired
Enterococci from a Multi-center Surveillance –
The ORION Study (C1-145)
12:15 p.m. – 1:15 p.m.
Poster
Draghi
In vitro Activity of Oritavancin Against Gram-positive Organisms in
Europe: A Comparative Study of Clinical Trial and Surveillance
Results (C1-144)
12:15 p.m. – 1:15 p.m.
Poster
Fritsche
Activity of Oritavancin Tested Against Contemporary Gram-positive
Pathogens Submitted to a Global Surveillance Program (2008)
12:15 p.m. – 1:15 p.m.
Poster
Pankuch
Activity of Oritavancin Against 200 Vancomycin Susceptible and
Non-Susceptible MRSA by MIC Testing (C1-186)
12:15 p.m. – 1:15 p.m.
Poster
Saravolatz
In vitro Activity of Oritavancin Against CA-MRSA, VISA and
Daptomycin-Non-Susceptible Staphylococcus aureus (DNSSA) (C1-187)
12:15 p.m. – 1:15 p.m.
Poster
Vashisht
Activity of Oritavancin Against S. aureus, S. epidermidis,
Enterococcus spp. and S. pneumoniae, Isolated from
Canadian Hospitals: Results of CANWARD 2007 (C1-146)
12:15 p.m. – 1:15 p.m.
Poster
Vaudaux
Comparative Activity of Oritavancin Against Methicillin-Resistant Staphylococcus
aureus (MRSA) Bloodstream Isolates from Geneva University
Hospital (C1-143)
Tuesday,
October 28
10:45 a.m.– 11:00 a.m.
Slides
Belley
Oritavancin (ORI) Combinations with Linezolid (LIN) and Nafcillin
(NAF) are Synergistic against Vancomycin (VAN)-Nonsusceptible Staphylococcus
aureus (SA) (C1-3720)
11:15 a.m. – 12:15 p.m.
Slides
McKay
Impact of Human Serum Albumin (HSA) on Oritavancin (ORI) In vitro
Activity against Enterococci (C1-3835)
About Oritavancin
Oritavancin is a novel semi-synthetic lipoglycopeptide antibiotic
candidate with potent bactericidal (killing) activity against a broad
spectrum of gram-positive bacteria. In its intravenous (IV) formulation,
the product candidate has been tested in over 2,400 individuals and has
completed two Phase 3 studies for the treatment of complicated skin and
skin structure infections (cSSSI) in which the primary endpoints were
met. Targanta submitted a New Drug Application (NDA) to the U.S. Food
and Drug Administration (FDA) in February 2008 seeking to commercialize
oritavancin for the treatment of cSSSI; the FDA accepted the NDA
submission for standard review, establishing an action date of December
8, 2008. Targanta’s Marketing Authorization
Application (MAA) for oritavancin was accepted for review by the
European Medicines Agency (EMEA) in June 2008. Targanta is also
developing an oral version of oritavancin for the possible treatment of Clostridium
difficile.
About Targanta Therapeutics
Targanta Therapeutics Corporation (Nasdaq: TARG) is a biopharmaceutical
company focused on developing and commercializing innovative antibiotics
to treat serious infections in the hospital and other institutional
settings. The Company’s pipeline includes an
intravenous version of oritavancin, a semi-synthetic lipoglycopeptide
antibiotic currently awaiting U.S. and EU regulatory approval, and, a
program to develop an oral version of oritavancin for the treatment of Clostridium
difficile. The Company has operations in Cambridge, MA,
Indianapolis, IN, and Montreal, Québec,
Canada. For more information on Targanta, visit www.targanta.com.
Safe Harbor Statement
This press release contains “forward-looking
statements” that are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act
of 1995. These are statements that are predictive in nature, that depend
upon or refer to future events or conditions or that include words such
as “may,” "will,"
"expects," "projects," "anticipates," "estimates," "believes,"
"intends," "plans," "should," "seeks," “hope”
and similar expressions. Such statements include oritavancin’s
potential to address the limitations of currently marketed therapies for
serious gram-positive infections. Forward-looking statements involve
known and unknown risks and uncertainties that may cause actual future
results to differ materially from those projected or contemplated in the
forward-looking statements. Forward-looking statements may be
significantly impacted by certain risks and uncertainties described in
Targanta’s filings with the Securities and
Exchange Commission. The risks and uncertainties referred to above
include, but are not limited to, risks related to Targanta’s
dependence on the success of oritavancin; delays in obtaining or a
failure to obtain regulatory approval for Targanta’s
product candidates; failure of any approved product to achieve
significant commercial acceptance in the medical community or receive
reimbursement by third-party payors; unfavorable clinical trial results;
failure to maintain and protect Targanta’s
intellectual property assets and to avoid infringing the intellectual
property rights of others; competition from other pharmaceutical or
biotechnology companies; Targanta’s potential
inability to initiate and complete pre-clinical studies and clinical
trials for its product candidates; the possibility that results of
pre-clinical studies are not necessarily predictive of clinical trial
results; and those other risks factors that are described more fully in
the Company’s filings with the Securities and
Exchange Commission. Targanta does not undertake any obligation to
update any of these forward-looking statements to reflect a change in
its views or events or circumstances that occur after the date of this
release.